Abstract
Currently the treatment of Alzheimers disease (AD) and Mild Cognitive Impairment (MCI) is largely unrealised, with no preventive or curative therapies. The marketed acetylcholinesterase inhibitors (eg. donepezil, Aricept) are directed toward temporary symptomatic relief from impaired cognition, but have prominent adverse effects with minimal efficacy. In pursuit of novel cognition enhancers, the observation that classical benzodiazepines (BZ, eg. diazepam) are amnesic, coupled with the preservation of GABAA receptors in brain areas most affected by AD, highlighted the GABAA receptor as a potential therapeutic target. In contrast to the amnesic BZ agonists, the BZ inverse agonists (eg. DMCM) which attenuate GABAA receptor function, have been shown to improve performance in animal models of learning and memory. Unfortunately, such nonselective ligands also induce anxiety and convulsions. More recently, novel ligands have been developed (eg. 6,6-dimethyl-3-(2-hydroxyethyl)thio-1-(thiazol-2-yl)-6,7-dihydro-2-benzothiophen-4(5H)-one) that demonstrate binding selectivity and high inverse agonism for the α5 GABAA receptor subtype, which is preferentially located in the hippocampus, a region of the brain associated with learning and memory. Preclinical results are encouraging, since these α5 selective inverse agonists enhance memory in animal models, such as spatial learning in the Morris water-maze, but are devoid of the adverse effects associated with activity at other GABAA receptor subtypes in other brain regions. If the efficacy and safety profiles of α5 inverse agonists in humans prove to be similar to those seen in pre-clinical studies, these compounds would offer significant benefit to AD and MCI patients.
Keywords: gaba, cognition, benzodiazepine, learning, memory, water-maze
Current Drug Targets - CNS & Neurological Disorders
Title: GABAA Receptor Subtype Selective Cognition Enhancers
Volume: 2 Issue: 4
Author(s): Karen Maubach
Affiliation:
Keywords: gaba, cognition, benzodiazepine, learning, memory, water-maze
Abstract: Currently the treatment of Alzheimers disease (AD) and Mild Cognitive Impairment (MCI) is largely unrealised, with no preventive or curative therapies. The marketed acetylcholinesterase inhibitors (eg. donepezil, Aricept) are directed toward temporary symptomatic relief from impaired cognition, but have prominent adverse effects with minimal efficacy. In pursuit of novel cognition enhancers, the observation that classical benzodiazepines (BZ, eg. diazepam) are amnesic, coupled with the preservation of GABAA receptors in brain areas most affected by AD, highlighted the GABAA receptor as a potential therapeutic target. In contrast to the amnesic BZ agonists, the BZ inverse agonists (eg. DMCM) which attenuate GABAA receptor function, have been shown to improve performance in animal models of learning and memory. Unfortunately, such nonselective ligands also induce anxiety and convulsions. More recently, novel ligands have been developed (eg. 6,6-dimethyl-3-(2-hydroxyethyl)thio-1-(thiazol-2-yl)-6,7-dihydro-2-benzothiophen-4(5H)-one) that demonstrate binding selectivity and high inverse agonism for the α5 GABAA receptor subtype, which is preferentially located in the hippocampus, a region of the brain associated with learning and memory. Preclinical results are encouraging, since these α5 selective inverse agonists enhance memory in animal models, such as spatial learning in the Morris water-maze, but are devoid of the adverse effects associated with activity at other GABAA receptor subtypes in other brain regions. If the efficacy and safety profiles of α5 inverse agonists in humans prove to be similar to those seen in pre-clinical studies, these compounds would offer significant benefit to AD and MCI patients.
Export Options
About this article
Cite this article as:
Maubach Karen, GABAA Receptor Subtype Selective Cognition Enhancers, Current Drug Targets - CNS & Neurological Disorders 2003; 2 (4) . https://dx.doi.org/10.2174/1568007033482779
DOI https://dx.doi.org/10.2174/1568007033482779 |
Print ISSN 1568-007X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-007X |
Related Articles
-
Clinical and Prognostic Implications of Cognitive Dysfunction and Depression in COPD
Current Respiratory Medicine Reviews Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Current Medicinal Chemistry Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Cerium Oxide Nanoparticles Trigger Neuronal Survival in a Human Alzheimer Disease Model By Modulating BDNF Pathway
Current Nanoscience Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Benzothiazoles - Scaffold of Interest for CNS Targeted Drugs
Current Medicinal Chemistry Treatment of Large Vessel Vasculitis
Current Immunology Reviews (Discontinued) COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry Review of 5-HT4R Ligands: State of Art and Clinical Applications
Current Topics in Medicinal Chemistry Quetiapine Modulates Conditioned Anxiety and Alternation Behavior in Alzheimer’s Transgenic Mice
Current Alzheimer Research New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Novel Pyrimidine based Semicarbazones: Confirmation of Four Binding Site Pharmacophoric Model Hypothesis for Antiepileptic Activity
Central Nervous System Agents in Medicinal Chemistry Cellular Balance, Genes,and the Huang Ti Nei Ching Su Wen
Current Neurovascular Research Topical Discoveries on Multi-Target Approach to Manage Alzheimer’s Disease
Current Drug Metabolism Opiate Drug Use and the Pathophysiology of NeuroAIDS
Current HIV Research The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Pharmacological Management of Acutely Agitated Schizophrenic Patients
Current Pharmaceutical Design Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design NF-κB as a Key Mediator of Brain Inflammation in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets